ARTICLE | Clinical News
CAT-192: Began Phase I/IIa study
November 19, 2001 8:00 AM UTC
Cambridge Antibody Technology Group plc (LSE:CAT; CATG), Melbourn, U.K. Genzyme General (GENZ), Cambridge, Mass. Product: CAT-192 Business: Antibodies, Dermatology Therapeutic category: Antibody Targ...